Loading stock data…
$3.24+0.04 (+1.25%)
X4 Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases of the immune system.
X4 Pharmaceuticals, Inc. in the Healthcare sector is trading at $3.24 with a market capitalization of $347M. Wall Street consensus targets $11.60 (5 analysts), implying a +258.0% move over the next 12 months. The stock is currently 33% below its 52-week high of $4.83, remaining 15.2% below its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the distress zone. The Whystock Score of 25/100 signals elevated caution as multiple indicators diverge.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $8.81M↑ | $2.71M↑ | $2.57M↑ | $1.76M↓ | $1.97M |
| Gross Profit | $7.19M↑ | $2.11M↓ | $2.20M↑ | $1.41M↓ | $1.65M |
| Operating Income | -$16.39M↑ | -$20.31M↑ | -$23.70M↑ | -$27.51M↓ | -$26.23M |
| Net Income | -$16.16M↑ | -$20.24M↑ | -$23.93M↑ | -$29.82M↓ | -$25.74M |
X4 Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases of the immune system. It offers XOLREMDI, an orally small-molecule selective a...